0001181431-13-059663.txt : 20131119 0001181431-13-059663.hdr.sgml : 20131119 20131119170057 ACCESSION NUMBER: 0001181431-13-059663 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20131115 FILED AS OF DATE: 20131119 DATE AS OF CHANGE: 20131119 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aegerion Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001338042 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 202960116 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 101 MAIN STREET STREET 2: SUITE 1850 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: (617) 500-7867 MAIL ADDRESS: STREET 1: 101 MAIN STREET STREET 2: SUITE 1850 CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Aegerion Pharmaceuticals Inc DATE OF NAME CHANGE: 20050906 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sumeray Mark CENTRAL INDEX KEY: 0001527134 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-34921 FILM NUMBER: 131230681 MAIL ADDRESS: STREET 1: 101 MAIN STREET STREET 2: SUITE 1850 CITY: CAMBRIDGE STATE: MA ZIP: 02142 4 1 rrd395678.xml FORM 4 X0306 4 2013-11-15 0 0001338042 Aegerion Pharmaceuticals, Inc. AEGR 0001527134 Sumeray Mark C/O AEGERION PHARMACEUTICALS, INC. 101 MAIN STREET, SUITE 1850 CAMBRIDGE MA 02142 0 1 0 0 Chief Medical Officer Common Stock 2013-11-15 4 M 0 2000 13.01 A 2000 D Common Stock 2013-11-15 4 S 0 489 74.9270 D 1511 D Common Stock 2013-11-15 4 S 0 1011 75.8908 D 500 D Common Stock 2013-11-15 4 S 0 500 77.634 D 0 D Stock Option (right to buy) 13.01 2013-11-15 4 M 0 2000 0 D 2021-11-01 Common Stock 2000 125000 D The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the "Plan"). The Plan was adopted for purposes of investment portfolio diversification. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.52 to $75.40, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.65 to $76.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.34 to $78.21, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. 100,000 shares of common stock underlying this option vest over a 46-month period, with one-twenty-fourth of the shares vesting on the grant date of November 1, 2011 and the remainder of the shares vesting monthly thereafter in forty-six equal installments; 30,000 shares of common stock underlying this option began to vest monthly in equal installments over a four-year period commencing upon the date of marketing approval of Juxtapid by the U.S. Food and Drug Administration; 20,000 shares of common stock underlying this option began to vest monthly in equal installments over a four-year period commencing upon the date of marketing approval of Lojuxta by the European Medicines Agency; and 10,000 shares of common stock underlying this option vest monthly in equal installments over a four-year period commencing upon approval of Juxtapid for the treatment of pediatric patients. By: /s/ Anne Marie Cook, attorney-in-fact 2013-11-19